D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)
The purpose of this study is to evaluate the safety and efficacy of chemotherapy combined with dendritic activated cytokine-induced killer cell (D-CIK) for non-small cell lung cancer (NSCLC).
Lung Cancer|Non-small Cell Lung Cancer
DRUG: Gemcitabine|DRUG: Cisplatin|BIOLOGICAL: D-CIK
Progress-free survival, 3 years
Overall survival, 3 years|Quality of life (QOL), The assessment will be performed using The European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC-QLQ-C30)., 3 years|Phenotypic analysis of T cells, The number of CD3+ (or CD8+ or CD4+ or CD56+) T cell, 1 year|Severity of adverse events, According to National Cancer Institute Common Terminology Criteria for Adverse Events（NCI-CTCAE), 1 year
60 patients with stage Ⅲb～Ⅳ NSCLC will be randomly divided into group A（receive D-CIK treatment and chemotherapy) or group B（just receive chemotherapy),and the randomize ratio will be 1:1. Patients in group A will receive 3 cycles of D-CIK treatment (every 1 months) and 4 cycles of chemotherapy (every 2 weeks).Patients in group B will receive only 4 cycles chemotherapy（every 2 weeks).